For example, PTPN2, known for its anti-inflammatory properties, emerges as a potential therapeutic target for both RA and pancreatic adenocarcinoma (PAAD) due to its ability to moderate inflammation and reduce tumor malignancy [53, 54]. Here, PTPN2 is linked to rheumatoid arthritis.